What it is
GHRP-6 stands for Growth Hormone Releasing Peptide 6. It is a man-made chain of six amino acids (a peptide) with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It was the first peptide shown to trigger powerful growth hormone release from the pituitary gland, developed in the 1980s by researcher Cyril Bowers at Tulane University. Every later peptide of this type, including GHRP-2, hexarelin and ipamorelin, came from that discovery.
It copies ghrelin, the hormone your stomach makes when you are hungry. Because of that it does two things at once: it tells the body to release growth hormone, and it makes you very hungry. That strong hunger is what sets GHRP-6 apart from every other peptide in its family.
That makes it useful if you struggle to eat enough — during a bulking phase, or while recovering from illness. For most other people the hunger and the wider side effect list make it a poor first choice compared with a cleaner option like ipamorelin.
It has been studied a lot, in animals and in people. Safety studies found it well tolerated when given into a vein in healthy volunteers, with no clash with heart medicines such as beta blockers. It has also been researched for heart protection, wound healing and organ protection, through a second docking point called CD36.
It comes as a dry powder in a sealed glass vial. You add bacteriostatic water (sterile water with a preservative so it keeps for weeks) — a step called reconstitution — then inject it just under the skin, which is called a subcutaneous injection. It is not viable by mouth or under the tongue, because stomach enzymes break it down.
GHRP-6 is a synthetic hexapeptide ghrelin mimetic and the original growth hormone secretagogue, developed in the 1980s by Cyril Bowers at Tulane University. Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, derived from met-enkephalin via computer modelling and structural modification. The unnatural D-amino acids confer its properties and abolish opioid activity. It established the class that produced GHRP-2, hexarelin and ipamorelin.
Its defining feature is potent orexigenic action. GHS-R1a agonism drives GH release and intense hunger simultaneously, which makes it a rational choice for hard gainers, aggressive bulking phases, recovery from illness, and cachexia or wasting states. Outside those contexts the broader hormonal profile — dose-dependent rises in cortisol, ACTH and prolactin — makes more selective secretagogues preferable.
Against GHRP-2: both are ghrelin mimetics acting in short pulsatile bursts and both are effective for muscle growth and recovery. GHRP-6 produces more intense appetite stimulation, more water retention, and a broader side effect profile with higher cortisol and prolactin effects. GHRP-2 sits as the middle ground between GHRP-6's aggressive profile and ipamorelin's clean one. GHRP-2 carries the greater desensitisation risk and produces more fatigue.
Beyond the somatotropic axis, GHRP-6 binds CD36, a second receptor expressed on cardiomyocytes, immune cells, vasculature and wound granulation tissue, producing cytoprotective effects that are independent of GH release.
Not orally or sublingually viable — gastric enzymes degrade it. Subcutaneous or intramuscular injection only.
How it works
Your body makes growth hormone using two signals. The first is GHRH from the hypothalamus, a part of the brain, which tells the pituitary gland to build up a supply of growth hormone. The second is ghrelin from the gut, which triggers the immediate release of what has been stored and also switches off somatostatin, the body's own brake on growth hormone. Think of GHRH as building the warehouse and ghrelin as emptying it while releasing the handbrake.
GHRP-6 copies ghrelin. It attaches to the ghrelin receptor (the docking point ghrelin normally uses, originally called the growth hormone secretagogue receptor) and sets off a chain of signals inside the cell involving calcium. Studies on human pituitary cells showed the effect starts within 15 minutes and peaks at 2 hours.
It works at three levels: directly on the pituitary to release growth hormone, on the hypothalamus to change how release is regulated from above, and on somatostatin to remove the brake. Research shows the hypothalamus is actually the main target in a living body.
The same ghrelin signal drives hunger. The stomach normally uses ghrelin to say it is empty, so GHRP-6 sets off that message too. The hunger usually hits 15 to 30 minutes after an injection and lasts 30 to 60 minutes.
GHRP-6 also attaches to a second docking point called CD36, found on heart muscle cells, immune cells and blood vessels. Through CD36 it switches on survival pathways inside cells, lowers damaging reactive oxygen species, boosts antioxidant defences and reduces inflammation. This effect does not depend on growth hormone at all.
Because GHRH and GHRP-6 use completely different routes, using both together gives far more growth hormone than either alone — which is why it is usually paired with a GHRH peptide such as CJC-1295.
GH secretion is governed by two signals: hypothalamic GHRH, which drives synthesis and increases the number of somatotrophs releasing GH, and gut-derived ghrelin, which triggers release of stored GH and suppresses somatostatin.
GHRP-6 is a ghrelin mimetic at GHS-R1a. Receptor binding activates the phosphatidylinositol second messenger system, leading to protein kinase C activation and mobilisation of intracellular calcium, which drives somatotroph degranulation. Lei et al. (1995) showed dose-dependent PI turnover in human pituitary somatotroph cells, detectable at 15 minutes and maximal at 2 hours, with parallel increases in GH secretion, confirming a PKC/calcium route rather than the cyclic AMP route used by GHRH. The receptor was named GHS-R before ghrelin was identified as its endogenous ligand in 1999.
Action is tripartite: direct pituitary stimulation, hypothalamic modulation of GH regulation, and somatostatin suppression. In vivo the hypothalamus is the major target — central injection stimulates GH release, and the effect is blocked by co-administered somatostatin.
The orexigenic effect reflects the same GHS-R1a signalling on hunger pathways and gastric emptying. GHRP-6's appetite effect exceeds GHRP-2's moderate stimulation (about 36% increase in food intake in one study) and ipamorelin's minimal effect.
A second receptor, CD36, mediates cytoprotection. CD36 binding activates prosurvival PI-3K/AKT1 signalling, reduces reactive oxygen species generation, enhances antioxidant defences and reduces inflammation. Cardioprotection was absent in CD36-null mice and CD36-deficient rats, and persisted in hypophysectomised animals, confirming a GH-independent mechanism.
GHRH synergy is well documented: GHRH raises the number of releasing cells while GHRP-6 raises output per cell and removes somatostatin inhibition, so simultaneous stimulation compounds the response.
What it does
Growth hormone: it produces strong, reliable pulses of growth hormone, and with them IGF-1, a second hormone that carries out much of growth hormone's muscle-building work. Levels peak about 15 minutes after an injection and return to normal within 90 to 120 minutes.
Appetite: it strongly increases hunger. This is its signature effect and its main advantage over other peptides in the class.
Muscle: higher growth hormone and IGF-1 support muscle protein synthesis, and the extra eating helps fuel it. In animal studies, daily use improved weight gain and feed efficiency significantly.
Fat: growth hormone breaks down stored fat by switching on an enzyme called hormone-sensitive lipase. But if the extra hunger pushes you into a constant calorie surplus, you will gain weight.
Repair: faster recovery between training sessions, less soreness, better healing of minor injuries, and more collagen, which helps skin, joints and bone.
Sleep: deeper sleep, with more growth hormone released overnight.
Immune system: it helps regulate immune function.
Heart and wounds: in animal studies it protected heart tissue and sped up wound closure. There is no human data for either.
Somatotropic axis: GHS-R1a agonism plus somatostatin suppression produces dose-dependent GH pulses with downstream IGF-1, supporting muscle protein synthesis. GH peaks at approximately 15 minutes and returns to baseline within 90 to 120 minutes.
Appetite: potent orexigenic effect, the strongest practical differentiator from GHRP-2 and from selective secretagogues such as ipamorelin. Onset 15 to 30 minutes, duration 30 to 60 minutes.
Metabolic: GH promotes lipolysis via hormone-sensitive lipase activation, shifting substrate use toward fat. Note the lipogenic caveat — circulating insulin and glucose at the time of dosing blunt the GH response and can direct the outcome toward fat gain, which is why fasted administration is specified rather than suggested. GH can also reduce insulin sensitivity and raise blood glucose.
Regenerative: enhanced tissue repair and recovery, increased collagen production benefiting skin, joints and bone.
Sleep architecture: improved slow-wave sleep with increased overnight GH secretion.
Immune: supports immune system regulation.
Cytoprotective (animal data only): CD36-mediated cardioprotection — infarct mass reduced by 78% in a pig model, protection against doxorubicin cardiotoxicity, preserved ventricular function after permanent coronary ligation. Wound healing effects include accelerated closure, reduced inflammatory infiltration, and anti-fibrotic action via PPARgamma activation.
Hormonal cost: dose-dependent increases in cortisol, ACTH and prolactin, significantly more pronounced than GHRP-2 or ipamorelin.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Strong, reliable growth hormone pulses, backed by over 40 years of research — GH peaks about 15 minutes after injection.Human trials
- Raises IGF-1, which drives lean muscle growth.Animal or lab only
- Strongly increases appetite, which helps hard gainers, bulking phases, and recovery from illness or surgery.Animal or lab only
- Breaks down stored fat when calories are kept under control.Anecdotal
- Faster recovery between sessions, less soreness and better healing of minor injuries.Anecdotal
- Increases collagen production, which helps skin, joints and bones.Anecdotal
- Deeper, more restorative sleep, especially when dosed before bed.Limited human data
- Supports the regulation of the immune system.Animal or lab only
- Protected heart tissue in several animal studies, an effect other peptides in this class do not share to the same degree.Animal or lab only
- Sped up wound closure and reduced scarring in animal studies.Animal or lab only
- Potent dose-dependent GH release with downstream IGF-1; peak at approximately 15 minutes, baseline by 90 to 120 minutes.Human trials
- Supports muscle protein synthesis; chronic administration improved average daily gain and feed efficiency in animal models.Animal or lab only
- Potent orexigenic effect — the defining advantage for hard gainers, bulking phases, post-illness recovery and cachexia or wasting conditions.Animal or lab only
- Promotes lipolysis via hormone-sensitive lipase, provided total caloric intake is managed.Anecdotal
- Enhanced tissue repair, reduced soreness and faster recovery between sessions.Anecdotal
- Increased collagen production for skin, joints and bone.Anecdotal
- Improved deep sleep with increased overnight GH secretion.Limited human data
- Supports immune system regulation.Animal or lab only
- CD36-mediated cardioprotection in animal models: 78% reduction in infarct mass in a pig model, protection against doxorubicin cardiotoxicity, preserved systolic function after permanent coronary ligation. No human trials.Animal or lab only
- Accelerated wound closure, reduced inflammatory infiltration and anti-fibrotic action via PPARgamma in animal models.Animal or lab only
What to expect
There is no published human data setting out timelines for body composition or performance with GHRP-6 as it is commonly used — daily injection under the skin for optimisation. What follows comes from user reports and clinical extrapolation.
Weeks 1 to 2. The growth hormone response and the hunger are immediate. Growth hormone peaks about 15 minutes after an injection and is back to normal within 90 to 120 minutes. The hunger hits 15 to 30 minutes after injecting and fades within 1 to 2 hours. Expect a big appetite increase — this is the most obvious effect — plus better sleep, especially with evening dosing, mild water retention, and possibly some passing tingling in the hands.
Weeks 2 to 4. Recovery between training sessions usually starts to improve. Early water retention settles. If the extra eating is being handled well, early body composition changes may start to show. The hunger stays consistent.
Weeks 4 to 8. The build-up of growth hormone and IGF-1 starts to show. Users report noticeable body composition changes, better skin quality, better recovery from training and fuller-looking muscles.
Weeks 8 to 16. Continued improvement. The peak growth hormone response may fade a little with daily use, though the hunger and growth effects continue. Research on hexarelin showed partial fading of the GH response reaching significance by 4 to 16 weeks, fully reversible after 4 weeks off.
Responses vary with age, body composition, training, sleep and nutrition. GHRP-6 amplifies what your training, food and sleep are already doing; it cannot make up for weak foundations. The intense hunger is a powerful tool for gaining muscle but will undermine fat loss if it is not managed deliberately.
No published human data establishes body composition or performance timelines for daily subcutaneous GHRP-6 as used in practice. The following reflects aggregated user reports and clinical extrapolation.
Weeks 1 to 2. Acute pharmacology is immediate: GH peaks at approximately 15 minutes, returns to baseline within 90 to 120 minutes; hunger onset 15 to 30 minutes post-injection, subsiding within 1 to 2 hours. Expect marked appetite increase as the dominant early effect, improved sleep quality with evening dosing, mild water retention and possible transient paraesthesia in the hands.
Weeks 2 to 4. Inter-session recovery improves. Initial fluid retention stabilises. Early body composition changes may emerge where caloric intake is controlled. The orexigenic effect remains consistent and does not meaningfully diminish.
Weeks 4 to 8. Cumulative GH and IGF-1 elevation becomes apparent: improved body composition, better skin quality, improved training recovery and enhanced muscle fullness.
Weeks 8 to 16. Continued body composition and performance gains. Some attenuation of the peak GH response may occur with chronic daily use, while the orexigenic and growth-promoting effects persist. Rahim and Shalet (1998) in hexarelin found partial attenuation reaching significance by 4 to 16 weeks and fully reversible after 4 weeks off.
User reports also describe significant water retention (more than GHRP-2 or ipamorelin), post-injection drowsiness, transient tingling or numbness in the hands, mood changes or irritability attributed to cortisol, and a wired or anxious feeling at higher doses. Some report the hunger intensity moderating after several weeks without disappearing.
Individual response varies with age, body composition, training status, sleep and nutrition. GHRP-6 amplifies existing inputs rather than substituting for them.
Reconstitution and dosing
No published dose-finding studies exist for the under-the-skin injection protocols used in practice. Human safety studies used escalating doses into a vein. The protocols below are clinical practice patterns, not trial-derived.
Mixing. The standard is a 5 mg vial reconstituted with 2 mL of bacteriostatic water. That gives 250 micrograms per 10 units on an insulin syringe. Add the water slowly down the inside wall of the vial and swirl gently — do not shake. If you have a 10 mg vial mixed with 3 mL instead, each unit on the syringe is about 33.3 micrograms, so 3 units is 100 micrograms and 15 units is 500.
Solo dose. 100 to 300 micrograms per injection, 2 to 3 times a day, every day, injected under the skin. Timing: morning, pre-workout, and/or before bed, always fasted. Run it for 8 to 16 weeks.
By body weight. Under 150 lbs: 100 to 150 micrograms per injection. 150 to 200 lbs: 150 to 200 micrograms. Over 200 lbs: 200 to 300 micrograms.
With CJC-1295. The preferred approach is 100 to 200 micrograms of GHRP-6 plus 100 to 200 micrograms of CJC-1295 without DAC per injection, 2 to 3 times daily, for 8 to 12 weeks. They can go in the same syringe.
Food. Inject on an empty stomach, at least 1 hour before eating or 2 to 3 hours after eating, and wait at least 30 minutes after injecting before you eat. Food, especially carbohydrates, raises insulin and blunts the growth hormone response.
Hunger as a tool. The hunger hits 15 to 30 minutes after injecting. Time the injection 30 minutes before your biggest meal so it lands when you are ready to eat.
Cycling. 12 to 16 weeks on, 4 weeks off, based on the hexarelin data. At 100 micrograms or below the cortisol and prolactin effects are smaller, though still present. Some older guidance uses lower daily totals — 100 to 200 micrograms a day for general wellness, 300 to 500 micrograms a day split over 2 to 3 injections for muscle growth.
No published dose-finding studies exist for subcutaneous bolus protocols. Human safety data used escalating intravenous doses; animal work ranged from single IV bolus to chronic daily subcutaneous administration. The following are clinical practice patterns.
Reconstitution. Standard is a 5 mg vial with 2 mL bacteriostatic water, giving 250 mcg per 10 units on an insulin syringe. Add diluent down the vial wall and swirl; do not shake. Use 0.3 mL (30 unit) barrels for accurate microdosing. A 10 mg vial with 3 mL yields 3.33 mg/mL, or 33.3 mcg per unit — 3 units = 100 mcg, 6 = 200, 9 = 300, 12 = 400, 15 = 500.
Solo. 100 to 300 mcg per injection, 2 to 3 times daily, subcutaneous, daily schedule, 8 to 16 week cycle. Timing: morning, pre-workout and/or pre-bed, fasted.
Body-weight tiers. Under 150 lbs: 100 to 150 mcg per injection. 150 to 200 lbs: 150 to 200 mcg. Over 200 lbs: 200 to 300 mcg.
With CJC-1295 (preferred). GHRP-6 100 to 200 mcg plus CJC-1295 without DAC 100 to 200 mcg per injection, 2 to 3 times daily, 8 to 12 weeks. Combining in the same syringe is acceptable. The pairing produces significantly more GH than either alone by engaging GHRH and ghrelin pathways simultaneously.
Fasting. Mandatory rather than preferential. Administer at least 1 hour before eating or 2 to 3 hours after a meal, with no food for at least 30 minutes post-injection; carbohydrate-driven insulin directly blunts the GH response and interacts with GHRP-6's lipogenic properties.
Appetite timing. Hunger onset is 15 to 30 minutes post-injection; dosing 30 minutes before the largest meal converts the side effect into a tool.
Cycling. 12 to 16 weeks on, 4 weeks off, extrapolated from hexarelin data showing roughly 45% attenuation of the GH response after 16 weeks of twice-daily use, fully reversed after 4 weeks off. Doses of 100 mcg or below minimise but do not eliminate cortisol and prolactin elevation; ipamorelin is the alternative where that profile is the limiting concern. Lower total-daily approaches also exist: 100 to 200 mcg/day for wellness, 300 to 500 mcg/day split over 2 to 3 administrations for performance.
Standard (solo), 5 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
2.5 mg/mL · 25 mcg per unit
Cycle: 8 to 16 weeks · Frequency: 2 to 3 times daily, fasted — morning, pre-workout and/or before bed
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 100 mcg | 4 units | Per injection, 2 to 3 injections daily |
| Full | 300 mcg | 12 units | Per injection, 2 to 3 injections daily |
Standard (with CJC-1295), 5 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
2.5 mg/mL · 25 mcg per unit
Cycle: 8 to 12 weeks · Frequency: 2 to 3 times daily, fasted, alongside 100 to 200 mcg CJC-1295 without DAC per injection
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 100 mcg | 4 units | Per injection, 2 to 3 injections daily, paired with CJC-1295 without DAC |
| Full | 200 mcg | 8 units | Per injection, 2 to 3 injections daily, paired with CJC-1295 without DAC |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 10 mg vial — anti-ageing / wellness protocol
Mix with 3 mL (300 units) of bacteriostatic water.
3.33 mg/mL · 33.33 mcg per unit
Cycle: 6–12 weeks, then a 2–4 week washout · Frequency: Once daily or split into two doses; fasted, no food for 30 minutes after
| When | Dose | Draw | How often |
|---|---|---|---|
| Daily total, low end | 100 mcg | 3 units | Daily total, taken as one injection or split across 2 |
| Daily total, top of range | 200 mcg | 6 units | Daily total, taken as one injection or split across 2 |
Alternative, 10 mg vial — performance / muscle growth protocol
Mix with 3 mL (300 units) of bacteriostatic water.
3.33 mg/mL · 33.33 mcg per unit
Cycle: 6–12 weeks, then a 2–4 week washout · Frequency: Split into 2–3 doses: morning on waking, post-workout, before bed; fasted, no food for 30 minutes after
| When | Dose | Draw | How often |
|---|---|---|---|
| Daily total, low end | 300 mcg | 9 units | Daily total, split across 2–3 injections (morning on waking; post-workout; before bed) |
| Daily total, top of range | 500 mcg | 15 units | Daily total, split across 2–3 injections (morning on waking; post-workout; before bed) |
5 mg in 2 mL is 2.5 mg/mL, or 25 mcg per unit. Draw 4 units (0.04 mL) for 100 mcg.
Who should avoid it
- Anyone allergic to GHRP-6.
- Anyone pregnant or breastfeeding — there is no safety data.
- Anyone with active cancer or tumours, because growth hormone and IGF-1 can speed up tumour growth.
- Anyone with a past cancer, unless an oncologist has cleared it.
- Anyone with diabetic retinopathy (eye damage from diabetes).
- Care needed with diabetes or pre-diabetes: growth hormone can raise blood sugar, so glucose needs watching closely and a doctor should be involved.
- Care needed with heart or blood vessel disease.
- Care needed with a history of carpal tunnel syndrome, as higher growth hormone can make symptoms worse.
- Anyone with an advanced brain or nerve disorder.
- Anyone who struggles to control eating, or has a history of an eating disorder — the hunger GHRP-6 causes can be destabilising.
- Anyone on insulin or diabetes tablets should expect blood sugar management to need adjusting.
- Steroid medicines (glucocorticoids) can blunt the growth hormone response.
- Known allergy to GHRP-6.
- Pregnancy and lactation — no safety data.
- Active malignancy or tumours: GH and IGF-1 elevation can accelerate tumour growth.
- History of malignancy — oncology consultation before use.
- Diabetic retinopathy.
- Diabetes or pre-diabetes: GH affects insulin sensitivity and glucose; close monitoring and physician supervision required.
- Cardiovascular disease.
- History of carpal tunnel syndrome — elevated GH can worsen symptoms.
- Advanced neurological disorders.
- Difficulty controlling appetite or history of eating disorders, given the potent orexigenic effect.
- Concurrent insulin or oral hypoglycaemics may require dose adjustment.
- Glucocorticoids may blunt the GH response. No pharmacological interaction was found with the beta-blocker metoprolol.
- Suggested monitoring: IGF-1 at 4 to 6 weeks, fasting glucose and HbA1c, and baseline plus periodic prolactin and cortisol, particularly at higher doses.
Side effects
- Intense hunger — the most noticeable effect. It starts 15 to 30 minutes after the injection and lasts 30 to 60 minutes. Helpful when bulking, a problem when cutting.
- Noticeable water retention and bloating, more than with GHRP-2 or Ipamorelin.
- Redness, swelling, or itching where you inject.
- Tingling or numbness in the hands, which passes.
- Drowsiness or fatigue, especially with an evening dose.
- A rise in cortisol (the stress hormone), prolactin, and ACTH. This is dose-related and stronger than with GHRP-2 or Ipamorelin. At 100 micrograms or less it is much smaller but still there.
- Joint stiffness from raised growth hormone.
- Headache.
- Mood changes or irritability, and anxiety at higher doses.
- Possible rise in blood sugar because growth hormone can reduce insulin sensitivity.
- Potent orexigenic effect: onset 15 to 30 minutes post-injection, duration 30 to 60 minutes. Consistent and does not meaningfully diminish, though intensity may moderate over weeks.
- Significant water retention and bloating, reported as greater than GHRP-2 or Ipamorelin.
- Injection site redness, swelling, itching.
- Transient paraesthesia or numbness in the hands.
- Drowsiness and fatigue, particularly with evening administration.
- Dose-dependent elevation of cortisol, ACTH, and prolactin, significantly more pronounced than GHRP-2 or Ipamorelin. Raun et al., 1998 found both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while Ipamorelin did not, even at doses more than 200 times the effective GH dose. At 100 mcg or less, cortisol and prolactin increases in most subjects were not meaningfully altered; higher doses produce progressively greater effects.
- Route modifies the profile: intravenous GHRP-6 consistently produces concurrent ACTH and cortisol rises alongside the GH pulse, intranasal gave a significant GH increase with a more modest ACTH response, and oral produced essentially no meaningful change in GH, ACTH, or cortisol.
- Joint stiffness secondary to elevated GH; headache; mood changes or irritability; anxiety at higher doses.
- Reduced insulin sensitivity with possible glucose elevation, a general secretagogue concern.
- Escalating intravenous dosing in healthy volunteers documented no adverse events (Berlanga-Acosta et al., 2017).
What the evidence shows
GHRP-6 was the first growth hormone releasing peptide, developed in the 1980s by Cyril Bowers at Tulane University, so it has over 40 years of research behind it.
How it works in the pituitary was mapped in human pituitary cells (Lei et al., 1995). GHRP-6 switched on a signalling system called phosphatidylinositol turnover — a chemical relay inside the cell — in a dose-dependent way. The effect showed up after 15 minutes and peaked at 2 hours, in all 8 tumours tested, with increases of 2.1 to 7.9-fold, and growth hormone went up alongside it.
Safety in people has been checked. A dose scale-up trial in healthy volunteers given GHRP-6 into the vein found no adverse events (Berlanga-Acosta et al., 2017), and no interaction with the heart medicine metoprolol.
The heart and healing research is all in animals. In pigs having a heart attack, infarct mass fell by 78% and infarct thickness by 50% (Berlanga et al., 2007). In rats, GHRP-6 protected the heart from the chemotherapy drug doxorubicin (Berlanga-Acosta et al., 2024), and improved heart pumping after a permanent artery tie-off when given for 7 days (Castro et al., 2026). A review found the protection was absent in mice lacking the CD36 receptor and still happened in animals without a pituitary gland, so it does not depend on growth hormone (Berlanga-Acosta et al., 2017). Wounds closed faster and scars were smaller in animals (Mendoza Mari et al., 2016), but it did not help scars that had already formed.
In pigs, the closely related GHRP-2 raised growth hormone with a peak at 15 minutes and a return to normal by 120 minutes, and daily use for 30 days kept working while improving weight gain and feed efficiency (Phung et al., 2000).
On tolerability, Ipamorelin was the first selective option and did not raise the stress hormones GHRP-6 does (Raun et al., 1998).
Important limit: no published studies have tested the daily under-the-skin doses people actually use.
GHRP-6 is the original synthetic growth hormone secretagogue, developed in the 1980s by Cyril Bowers at Tulane, derived from met-enkephalin by computer modelling; the D-amino acids in His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 remove opioid activity.
Mechanism: Lei et al., 1995 showed dose-dependent phosphatidylinositol turnover in human pituitary somatotroph cells, detectable at 15 minutes and maximal at 2 hours, present in all 8 tumours examined at 2.1 to 7.9-fold increases, with parallel GH secretion — confirming PKC and calcium mobilisation signalling rather than cyclic AMP as used by GHRH.
Safety: a dose scale-up trial of escalating intravenous GHRP-6 in healthy volunteers documented no adverse events (Berlanga-Acosta et al., 2017), with no pharmacological interaction with metoprolol.
Cytoprotection via CD36: Berlanga et al., 2007 reduced infarct mass by 78% and infarct thickness by 50% in a pig acute myocardial infarction model, with more than 50% of treated pigs free of pathological Q waves, mediated by reduced reactive oxygen species and preserved antioxidant defence. Berlanga-Acosta et al., 2024 prevented doxorubicin-induced myocardial fibre damage and ventricular dilation in rats, preserving left ventricular systolic function via sustained antioxidant defence, Bcl-2 upregulation, and PI-3K/AKT1 prosurvival signalling. Castro et al., 2026 attenuated post-infarct ventricular dysfunction after permanent left descending coronary ligation, dosed for 7 days post-surgery. The 2017 cytoprotective review (Berlanga-Acosta et al.) documented GHS-R1a and CD36 dual binding, rescue of over 70% of the area at risk, absent cardioprotection in CD36-null mice, and retained cardioprotection in hypophysectomised animals — GH-independent.
Wound healing: Mendoza Mari et al., 2016 showed accelerated closure within the first 24 hours, reduced mononuclear infiltration, and reduced hypertrophic scarring via PPARgamma activation and lower fibrogenic cytokine expression; ineffective on established scars.
Kinetics and chronic use: Phung et al., 2000 (GHRP-2 in swine) showed dose-dependent GH release peaking at 15 minutes, baseline by 120 minutes, sustained over 30 days with improved average daily gain and feed efficiency. Rahim and Shalet, 1998 dosed 12 healthy elderly subjects twice daily with hexarelin for 16 weeks: GH AUC fell from 19.1 to 10.5 by week 16 and returned to 19.4 after 4 weeks off. Selectivity is defined by Raun et al., 1998. No published dose-finding studies exist for the subcutaneous bolus protocols used in practice.
User reports
From public forums
These notes come from public reports on Reddit, peptide forums, and bodybuilding sites. They are anecdotal and do not carry the weight of published research.
Hunger is what almost everyone talks about. Users describe overwhelming hunger starting 15 to 30 minutes after the injection and lasting 30 to 60 minutes, sometimes close to painful. Hard gainers and people bulking see this as the main benefit. Anyone trying to hold a calorie deficit, or even a small surplus, finds it hard work. Several report the intensity easing after a few weeks, but it never fully goes.
Body composition reports split by how well nutrition is managed. Those who track intake report less body fat, fuller muscles, and better skin. Those who do not often report weight gain that includes both muscle and fat.
Sleep is widely reported as deeper and more restorative, usually within the first week, especially with an evening dose.
Recovery between sessions is commonly described as faster, with less soreness and more training capacity.
Side effects reported most often, beyond hunger, are noticeable water retention (more than GHRP-2 or Ipamorelin), drowsiness after the injection, short-lived tingling or numbness in the hands, and mood changes or irritability that users put down to cortisol. A few feel wired or anxious at higher doses.
The most popular protocol is GHRP-6 with CJC-1295 without DAC at 100 to 200 micrograms of each, 2 to 3 times daily. Users consistently say the pair beats either alone.
Where practice differs from the research: most people choose Ipamorelin for general use because GHRP-6's side effects are broader, and reserve GHRP-6 for hard gainers or aggressive bulking. Some run 100 micrograms or less to keep cortisol and prolactin down while keeping the appetite effect.
Aggregated from external platforms including Reddit, peptide forums, and bodybuilding boards; anecdotal and not equivalent to published research.
The orexigenic effect dominates reports: overwhelming hunger at 15 to 30 minutes post-injection lasting 30 to 60 minutes, described by some as nearly painful. Valued by hard gainers and those in bulking phases, poorly tolerated by anyone holding a deficit or modest surplus. Several report partial attenuation of intensity over several weeks without full disappearance, consistent with sustained GHS-R1a stimulation.
Body composition outcomes track nutritional discipline. Users managing intake report reduced body fat, improved muscle fullness, and better skin quality comparable to other GHRPs; those who do not report weight gain comprising both lean and fat mass.
Sleep quality improvement is widely reported with evening dosing, often within the first week. Faster inter-session recovery and reduced soreness are commonly described.
Reported adverse effects beyond hunger: significant water retention exceeding GHRP-2 or Ipamorelin, post-injection drowsiness, transient hand paraesthesia or numbness, and mood changes or irritability attributed to cortisol. A minority describe feeling wired or anxious at higher doses.
The dominant stacking pattern is GHRP-6 with CJC-1295 without DAC at 100 to 200 mcg each, 2 to 3 times daily, reported as substantially more effective than either alone.
Where practice diverges from the literature: most users prefer Ipamorelin for general optimisation given GHRP-6's broader hormonal profile, reserving GHRP-6 for hard gainers or aggressive bulking. Some run 100 mcg or below specifically to minimise cortisol and prolactin effects while retaining the appetite benefit.
Reported timelines: appetite increase, improved sleep, mild water retention, and possible transient hand tingling in weeks 1 to 2; recovery gains and stabilising water retention by weeks 2 to 4; body composition, skin quality, and muscle fullness changes by weeks 4 to 8; continued gains with possible partial attenuation of the peak GH response through weeks 8 to 16.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
This is the standard pairing and the one users rate most highly. CJC-1295 tells the pituitary to build up more growth hormone; GHRP-6 releases it and takes the brake off. Together they produce far more growth hormone than either alone. Typical practice is 100 to 200 micrograms of each, 2 to 3 times daily, fasted, and they can go in the same syringe.
The canonical GHRH-analogue plus GHRP pairing. CJC No DAC raises the number of somatotrophs secreting at the GHRH receptor while GHRP-6 increases output per cell and suppresses somatostatin at GHS-R1a, and the synergy is well documented in the published literature. Practical pattern: 100 to 200 mcg of each per injection, 2 to 3 times daily, fasted, combinable in one syringe, 8 to 12 week cycles.
Better thought of as the alternative than the partner. Ipamorelin gives similar growth hormone release without the strong hunger, cortisol, or prolactin effects, so it is the cleaner choice unless the appetite boost is specifically wanted.
Positioned as a substitution rather than a stack: Raun et al., 1998 showed Ipamorelin does not release ACTH or cortisol above GHRH-stimulated levels even at doses more than 200 times the effective GH dose, making it preferable for general optimisation and for anyone on a GLP-1. Prior practice also paired it with GHRP-6 for additional GHS-R agonism with minimal cortisol and prolactin impact.
Not recommended alongside GHRP-6. Both work on the same receptor and compete with each other, so the better approach is to pick one and pair it with a growth hormone releasing hormone peptide such as CJC-1295. GHRP-2 on its own gives moderate hunger and fewer hormonal side effects.
Avoid combining. Both are GHS-R1a agonists competing for the same receptor pool, so a GHRH analogue is the mechanistically distinct partner. GHRP-2 sits between GHRP-6's aggressive profile and Ipamorelin's clean one, with moderate appetite stimulation (about 36% increase in food intake in one study) and lower cortisol and prolactin impact than GHRP-6.
It boosts muscle recovery and growth downstream of the growth hormone effect.
Supplies the downstream effector directly rather than relying on hepatic IGF-1 output, boosting recovery and hypertrophy.
No interaction concerns — completely different mechanisms. BPC-157 does not need to be taken fasted, so inject it whenever suits and keep GHRP-6 on its own fasted schedule. Higher growth hormone may help healing, although this exact pairing has not been tested.
No interaction concerns, distinct mechanisms. GHRP-6 requires fasted administration; BPC-157 does not, so timing can be decoupled. Elevated GH may complement healing effects, though no published research has tested the combination.
No interaction concerns. Different mechanism, no fasting needed, so it can be injected at any time while GHRP-6 stays on its fasted schedule.
No interaction concerns and no fasting requirement, so it runs independently of GHRP-6's fasted window. Elevated GH may complement tissue repair, untested in published combination research.
- GLP-1 agonists (retatrutide, semaglutide, tirzepatide)
No interaction concerns, but they pull in opposite directions on hunger. A GLP-1 strongly suppresses appetite while GHRP-6 strongly raises it. If fat loss on a GLP-1 is the goal, Ipamorelin is the better growth hormone peptide to pair with it.
No interaction concerns mechanistically, but a pharmacological tug-of-war on hunger signalling: GLP-1 receptor agonism markedly suppresses appetite against GHRP-6's orexigenic GHS-R1a drive. Ipamorelin is the preferred secretagogue alongside a GLP-1.
- Testosterone replacement therapy
No interaction concerns and it can be run alongside TRT. The effects may complement each other, as growth hormone supports fat use and recovery while testosterone supports muscle building.
No interaction concerns. Complementary anabolic routes: GH supports lipid metabolism and recovery while testosterone drives muscle protein synthesis through a separate pathway.
Sometimes used to blunt the hunger GHRP-6 causes, which helps when trying to change body composition rather than gain weight.
Used as an appetite suppressant to counteract GHRP-6's orexigenic effect, particularly during recomposition.
Common questions
Why choose GHRP-6 over Ipamorelin?
The one strong reason is the intense hunger. If you are a hard gainer who cannot eat enough to grow, GHRP-6 fixes that problem directly. For everyone else, Ipamorelin gives similar growth hormone release with a much cleaner profile — no cortisol spikes, no prolactin issues, no overwhelming hunger.
The only strong indication is deliberate appetite stimulation, for hard gainers or aggressive bulking. Otherwise Ipamorelin delivers comparable GH release without meaningful ACTH, cortisol, or prolactin involvement (Raun et al., 1998), making it the default for general optimisation.
How does GHRP-6 compare to GHRP-2?
GHRP-6 causes more intense hunger and has a broader side effect profile, with higher cortisol and prolactin effects. GHRP-2 sits in the middle between GHRP-6 and Ipamorelin: moderate hunger, fewer hormonal side effects. Pick GHRP-6 only if maximum appetite stimulation is the goal.
GHRP-6 carries stronger orexigenic drive and a broader hormonal footprint (greater cortisol and prolactin elevation) than GHRP-2, which occupies the middle ground between GHRP-6 and Ipamorelin. GHRP-2 produced about a 36% increase in food intake in one study against GHRP-6's markedly stronger effect.
Is the hunger manageable?
Most users describe it as intense but short — usually 30 to 60 minutes. The practical trick is to inject 30 minutes before a planned meal so the hunger arrives when food is ready. Some report the intensity easing over several weeks, but it never fully disappears.
Intense but time-limited, typically 30 to 60 minutes with onset at 15 to 30 minutes post-injection. Timing administration 30 minutes before the largest meal converts the effect into a tool. Reported intensity may moderate over weeks without resolving.
Does it have to be taken on an empty stomach?
Yes. Food, especially carbohydrate, raises insulin and directly blunts the growth hormone response. Dose at least 1 hour before eating, or 2 to 3 hours after the last meal, and wait at least 30 minutes after injecting before eating.
Yes. Carbohydrate-driven insulin elevation blunts the GH response, and circulating insulin and glucose interact with GHRP-6's lipogenic properties. Dose at least 1 hour pre-prandially or 2 to 3 hours post-prandially, with a minimum 30 minute post-injection fast.
Does GHRP-6 need to be cycled?
Research on hexarelin, a related peptide, showed the growth hormone response partly weakens with constant daily use, becoming significant somewhere between 4 and 16 weeks, and fully recovering after 4 weeks off. A cycle of 12 to 16 weeks on and 4 weeks off is a sensible approach. Some people run it continuously, but cycling is better supported.
Rahim and Shalet, 1998 showed partial, fully reversible attenuation with twice-daily hexarelin: GH AUC fell from 19.1 to 10.5 by week 16 and returned to 19.4 after 4 weeks off, roughly a 45% reduction from baseline. On that basis 12 to 16 weeks on with 4 weeks off preserves GHS-R sensitivity. Continuous use is practised but less well supported.
Does GHRP-6 affect blood sugar?
It can. Growth hormone reduces insulin sensitivity, and published research flags some concern about blood glucose rising with growth hormone secretagogues. Anyone with diabetes or pre-diabetes should monitor glucose closely and speak to a doctor first.
GH elevation reduces insulin sensitivity, and published research indicates concern for glucose increases with secretagogues generally. Diabetic and pre-diabetic users require close glucose monitoring, physician oversight, and possible adjustment of insulin or oral hypoglycaemics. Fasting glucose and HbA1c are part of standard monitoring.
Is GHRP-6 cardioprotective in humans?
Not proven. Every cardioprotection result comes from animal studies. The animal evidence is strong — several studies, a clear mechanism through the CD36 receptor, and confirmation in mice bred without that receptor — but no human trial has tested it.
No. All cardioprotection data derives from animal models, including Berlanga et al., 2007, Berlanga-Acosta et al., 2024, and Castro et al., 2026. The CD36-dependent mechanism is well supported, absent in CD36-null mice and retained in hypophysectomised animals, but no human trials exist.
Can GHRP-6 be stacked with another GHRP?
No. Two GHRPs bind the same receptor and compete with each other, so nothing is gained. Choose one GHRP and pair it with a growth hormone releasing hormone peptide such as CJC-1295 without DAC for the synergistic effect.
No. Multiple GHRPs compete for the same GHS-R1a pool and compound desensitisation risk without adding a distinct mechanism. Pair a single GHRP with a GHRH analogue such as CJC-1295 without DAC, which recruits a separate receptor pathway for true synergy.
References
- Lei T, Buchfelder M, Fahlbusch R, Adams EF. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J Mol Endocrinol. 1995;14(1):135-138.
- Berlanga J, Cibrian D, Guevara L, Dominguez H, Alba JS, Seralena A, Guillen G, Lopez-Mola E, Lopez-Saura P, Rodriguez A, Perez B, Garcia D, Vispo NS. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-250.
- Berlanga-Acosta J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024;15:1402138.
- Castro J, Shaikh I, et al. Growth hormone-releasing peptide-6 (GHRP-6) ameliorates post-infarct ventricular remodeling and systolic dysfunction in a model of permanent coronary ligation. Pharmaceuticals. 2026;19(3):468.
- Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
- Mendoza Mari Y, Fernandez Mayola M, Aguilera Barreto A, Garcia Ojalvo A, Bermudez Alvarez Y, Mir Benitez AJ, Berlanga Acosta J. Growth hormone-releasing peptide 6 enhances the healing process and improves the esthetic outcome of the wounds. Plast Surg Int. 2016;2016:7340426.
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl A:141-143.
- Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Peptides. 1997;18(6):885-891.
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329.
- Phung LT, Inoue H, Nou V, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Domest Anim Endocrinol. 2000;18(3):279-291.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.